Cytomegalovirus proctitis as a complication of COVID-19 with immunosuppressive treatments

François Maillet; Annabelle Pourbaix; Diane le Pluart; Laura Sirmai; Speranta Andreea Postolache; Anne Couvelard; Nadhira Houhou-Fidouh; Lisa Males; Laurène Deconinck; François-Xavier Lescure

doi:10.1016/j.idcr.2021.e01111

Cytomegalovirus proctitis as a complication of COVID-19 with immunosuppressive treatments

IDCases. 2021:24:e01111. doi: 10.1016/j.idcr.2021.e01111. Epub 2021 Apr 5.

Affiliations

¹ Infectious Diseases Department, AP-HP Bichat Claude-Bernard Hospital, 75018, Paris, France.
² Hepatogastroenterology Department, AP-HP Bichat Claude-Bernard Hospital, 75018, Paris, France.
³ Pathology Department, AP-HP Bichat Claude-Bernard Hospital, 75018, Paris, France.
⁴ Virology Department, AP-HP Bichat Claude-Bernard Hospital, 75018, Paris, France.
⁵ Radiology Department, AP-HP Bichat Claude-Bernard Hospital, 75018, Paris, France.

Abstract

We report a case of reactivated biopsy-proven cytomegalovirus proctitis complicating the course of severe COVID-19 pneumonia treated with dexamethasone, anakinra and lopinavir/ritonavir. No other contributing factor was found than iatrogenic immunosuppression and COVID-19 immune dysregulation. We draw attention to the immunosuppressive risk when treating severe COVID-19 pneumonia with immunomodulators.

Keywords: Anakinra; COVID-19; Cytomegalovirus infections; Dexamethasone; Proctitis; Rectal diseases.

Publication types

Case Reports